Thermo Fisher Scientific(US:TMO)2023-02-01 18:04Financial Data and Key Metrics Changes - In Q4, the company achieved a 14% core organic revenue growth and reported revenue growth of 7% year-over-year, with $370 million in testing revenue [2][57] - For the full year, reported revenue increased by 15% to $44.92 billion, with adjusted EPS of $23.24 per share [81][96] - The adjusted tax rate for the full year was 13%, a decrease of 160 basis points from 2021 [6] - Adjusted ROIC was 13.5%, indicating strong returns on investment [7] Business Line Data and Key Metrics Changes - Life Sciences Solutions segment reported a revenue decline of 27% in Q4, with organic revenue down 24% compared to the prior year [8] - Specialty Diagnostics segment saw a 23% decline in reported revenue and a 20% decline in organic revenue in Q4, primarily due to lower COVID-19 testing revenue [9] - The Laboratory Products and Biopharma Services segment reported a 42% increase in revenue in Q4, with organic growth of 11% [106] Market Data and Key Metrics Changes - North America grew in the low single digits, Europe declined in the high single digits, while Asia Pacific grew in the high single digits, including China [3] - The company expects a return to more normal market growth conditions in 2023, estimating core organic revenue growth of 7% [11][59] Company Strategy and Development Direction - The company continues to focus on high-impact innovation, leveraging scale in high-growth markets, and delivering unique value propositions to customers [124] - The Binding Site acquisition is expected to contribute approximately $250 million to reported revenue growth in 2023 [109] - The company aims for a 50% reduction in greenhouse gas emissions by 2030 as part of its ESG priorities [1] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the complexities of the current operating environment, including inflation and supply chain challenges [91][126] - The outlook for 2023 includes expectations of $45.3 billion in revenue and adjusted EPS of $23.70, despite a headwind from reduced testing revenue [107][96] - Management highlighted the importance of maintaining strong performance in the bioproduction business and the overall positive long-term prospects [46][24] Other Important Information - The company returned $3.5 billion to shareholders through stock buybacks and dividends in 2022 [95] - Free cash flow for the year was $6.94 billion after net capital expenditures of $2.2 billion [134] Q&A Session Summary Question: Concerns about near-term drag on revenue growth for biologic drug products - Management acknowledged industry concerns but expressed confidence in the company's resilience and ability to manage growth effectively [23] Question: Demand side visibility and order trends for 2023 - Management indicated that while there may be normalization in growth, they expect strong performance in the second half of the year [24] Question: Performance of the Analytical Instruments business - Management reported strong execution and good market conditions, with no significant changes in Q4 compared to Q3 [116] Question: Margin outlook for 2023 - Management indicated that gross margins are expected to hold steady, with a focus on maintaining strong operating income [117]